Overview

A Phase 2b Diabetic Kidney Disease Study

Status:
Recruiting

Trial end date:
2023-04-17

Target enrollment:

Participant gender:

Summary

A Phase 2b Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of MEDI3506 in Subjects with Diabetic Kidney Disease

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca

Treatments:

Dapagliflozin